Journal article

Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer

Kim Tam Bui, Melina L Willson, Shom Goel, Jane Beith, Annabel Goodwin

Cochrane Database of Systematic Reviews | WILEY | Published : 2020


BACKGROUND: Approximately 80% of breast cancers amongst premenopausal women are hormone receptor-positive. Adjuvant endocrine therapy is an integral component of care for hormone receptor-positive breast cancer and in premenopausal women includes oestrogen receptor blockade with tamoxifen, temporary suppression of ovarian oestrogen synthesis by luteinising hormone releasing hormone (LHRH) agonists, and permanent interruption of ovarian oestrogen synthesis with oophorectomy or radiotherapy. Recent international consensus statements recommend single-agent tamoxifen or aromatase inhibitors with ovarian function suppression (OFS) as the current standard adjuvant endocrine therapy for premenopaus..

View full abstract


Awarded by National Institute for Health Research (NIHR) Cochrane Incentive Award 2018

Funding Acknowledgements

This project is funded by the National Institute for Health Research (NIHR) Cochrane Incentive Award 2018 (NIHR 128381). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care, UK.